MSN Labs to produce Covid drug in collaboration with Baricitinib


Hyderabad: The city-based MSN Labs (MSN) has entered into a royalty free, non-exclusive, voluntary license agreement with Eli Lilly and Company of USA for manufacturing and marketing of baricitinib for Covid-19 in India.

The drug baricitinib has been granted a restricted emergency use approval in India by the Central Drugs Standard Control Organization (CDSCI) only in combination with remdesivir for the treatment of suspected or laboratory confirmed Covid-19 in hospitalized adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

Dr. MSN Reddy, CMD – MSN Group, commented “This Collaboration with Eli Lilly and Company is a landmark milestone in India’s fight against Covid-19 and will thus help in increasing the availability and affordability of baricitinib”.

MSN will also be launching the product under the brand name BARIDOZ in two strengths 2 mg & 4mg. MSN has developed the active pharmaceutical ingredient and the formulation of baricitinib in its in-house R&D and manufacturing units.

As part of the Covid treatment range, MSN has already launched FAVILOW (Favipiravir) in the strengths of 200mg, 400mg & 800mg and OSELOW (Oseltamivir) as 75 mg capsules.